Ultrahypofractionation Should Be a Standard of Care Option for Intermediate-Risk Prostate Cancer

Clinical Oncology - United Kingdom
doi 10.1016/j.clon.2019.11.004
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Expending the Paradigm: Active Surveillance for Intermediate Risk Prostate Cancer

Open Journal of Urology
2018English

Insignificant Disease Among Men With Intermediate-Risk Prostate Cancer

World Journal of Urology
Urology
2014English

Hypofractionation and Prostate Cancer: A Good Option for Africa?

South African Journal of Oncology
2017English

Should Blood Glucose Measurement Be a Standard of Monitoring?

Anaesthesia
AnesthesiologyPain Medicine
2017English

Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2015English

What Should Be the Prostate Specific Antigen Threshold for Prostate Biopsy?

Haseki Tip Bulteni
Medicine
2017English

Hypofractionated Stereotactic Body Radiation Therapy as Monotherapy for Intermediate-Risk Prostate Cancer

Radiation Oncology
Nuclear MedicineRadiologyImagingOncology
2013English

Primary Treatments for Intermediate-Risk Prostate Cancer: A Cost-Effectiveness and Value-Of-Information Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Successful Phase 2 Trial of Ultrafocal Brachytherapy for Low/Intermediate Risk Prostate Cancer

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy